XML 33 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Note 2 - Significant Accounting Policies (Details Textual)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Dec. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Jan. 01, 2019
USD ($)
Dec. 31, 2018
USD ($)
Impairment of Long-Lived Assets Held-for-use     $ 0            
Number of Operating Segments     1            
Cumulative Effect of New Accounting Principle in Period of Adoption   $ 346,139 $ 346,139 $ 343,570 $ 755,631 $ 64,622 $ 69,413   $ 41,398
Retained Earnings [Member]                  
Cumulative Effect of New Accounting Principle in Period of Adoption   94,786 $ 94,786 $ 97,312 $ 430,929 $ (255,566) $ (249,416)   $ (237,700)
Accounting Standards Update 2016-02 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member] | Retained Earnings [Member]                  
Cumulative Effect of New Accounting Principle in Period of Adoption               $ 0  
Furniture and Fixtures [Member]                  
Property, Plant and Equipment, Useful Life (Year)     7 years            
Office Equipment [Member]                  
Property, Plant and Equipment, Useful Life (Year)     5 years            
Equipment [Member]                  
Property, Plant and Equipment, Useful Life (Year)     5 years            
Vehicles [Member]                  
Property, Plant and Equipment, Useful Life (Year)     5 years            
Mobile Facility [Member]                  
Property, Plant and Equipment, Useful Life (Year)     27 years 6 months            
Building [Member]                  
Property, Plant and Equipment, Useful Life (Year)     39 years            
Fair Value, Recurring [Member]                  
Assets, Fair Value Disclosure   0 $ 0            
Janssen [Member] | Manufacturing Revenue [Member]                  
Clinical Manufacturing Agreement, Quarterly Payments to Be Received     $ 4,500            
Proceeds from Customers $ 4,500 $ 4,500              
Janssen [Member] | Clinical Trial Service Revenue [Member]                  
Transition Services Agreement, Number of Ongoing Clinical Trials Entered Into 2